Abstract
Rett syndrome (RTT) is an X-linked disorder caused by mutations in MECP2 in majority of cases. It is characterized by arrested development between 6 and 18 months of age, regression of acquired hand skills and speech, stereotypic hand movements, gait abnormalities and seizures. There are a very few studies in India which illustrates mutation spectrum in RTT. None of the studies have correlated seizures with the genotype. This study describes the phenotype and genotype spectrum in children with RTT syndrome and analyses the association of epilepsy with various clinical features and molecular findings. All children with RTT in our cohort had global developmental delay. Genetic diagnosis identified mutations of the MECP2 in all 25 children where RTT was suspected. We have identified point mutations in 20 patients, one insertion and four deletions by Sanger sequencing, namely c.1164_1207 (44 bp), c.1165_1207 (43 bp), c.1157_1197 (41 bp) del and c.1157_1188 (32 bp). Clinically, none of the patients with deletion had seizures. We identified one novel insertion variant c.337_338 (p.S113Ffs*9). All the deletions were located in the C-terminal region. Majority of the mutations (22/25) were identified in exon 4 which comprised of nonsense and missense types. Screening of hotspot mutations in exon 4 should be the first line evaluation in diagnosis of RTT. Molecular testing could help in specific management of seizures in RTT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amir R. E. and Zoghbi H. Y. 2000 Rett syndrome: Methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations. Am. J. Med. Genet. 97, 147–152.
Amir R. E., Van den Veyver I. B., Wan M., Tran C. Q., Francke U. and Zoghbi H. Y. 1999 Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185–188.
Bao X., Downs J., Wong K., Williams S. and Leonard H. 2013 Using a large international sample to investigate epilepsy in Rett syndrome. Dev. Med. Child Neurol. 55, 553-558.
Cardoza B., Clarke A., Wilcox J., Gibbon F., Smith P., Archer H. et al. 2011 Epilepsy in Rett syndrome: Association between phenotype and genotype, and implications for practice. Seizure: J. Br. Epilepsy Assoc. 20, 646–649.
Cheadle J. P. 2000 Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum. Mol. Genet. 9, 1119–1129.
d’Orsi G., Trivisano M., Luisi C., Demaio V., Claudio M., Pascarella M et al. 2012 Epileptic seizures, movement disorders, and breathing disturbances in Rett syndrome: diagnostic relevance of video-polygraphy. Epilepsy Behav. 25, 401–407.
Das D. K., Raha S., Sanghavi D., Maitra A. and Udani V. 2013 Spectrum of MECP2 gene mutations in a cohort of Indian patients with Rett syndrome: report of two novel mutations. Gene 515, 78–83.
De Bona C., Zappella M., Hayek G., Meloni I., Vitelli F., Bruttini M et al. 2000 Preserved speech variant is allelic of classic Rett syndrome. Eur. J. Hum. Genet. 8, 325–330.
Dragich J., Houwink-Manville I. and Schanen C. 2000 Rett syndrome: a surprising result of mutation in MECP2. Hum. Mol. Genet. 9, 2365–2375.
Guy J., Alexander-Howden B., FitzPatrick L., DeSousa D., Koerner M. V., Selfridge J. et al. 2018 A mutation-led search for novel functional domains in MeCP2. Hum. Mol. Genet. 27, 2531–2545.
Hagberg B., Aicardi J., Dias K. and Ramos O. 1983 A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann. Neurol. 14, 471–479.
Hoffbuhr K., Devaney J. M., LaFleur B., Sirianni N., Scacheri C., Giron J. et al. 2001 MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 56, 1486–1495.
Ip J. P. K., Mellios N. and Sur M. 2018 Rett syndrome: Insights into genetic, molecular and circuit mechanisms. Nat. Rev. Neurosci. 19, 368–382.
Jian L., Nagarajan L., Klerk N., Ravine D., Bower C., Anderson A. et al. 2006 Predictors of seizure onset in Rett syndrome. J. Pediatr. 149, 542–547.
Kyle S. M., Vashi N. and Justice M. J. 2018 Rett syndrome: A neurological disorder with metabolic components. Open Biol. 8, 170216.
Laccone F., Huppke P., Hanefeld F. and Meins M. 2001 Mutation spectrum in patients with Rett syndrome in the German population: Evidence of hot spot regions. Hum. Mutat. 17, 183–190.
Lallar M., Rai A., Srivastava P., Mandal K., Gupta N., Kabra M et al. 2018 Molecular testing of MECP2 gene in Rett syndrome phenotypes in Indian girls. Indian J. Pediatr. 55, 474–477.
Lee S. S. J., Wan M. and Francke U. 2001 Spectrum of MECP2 mutations in Rett syndrome. Brain Dev. 23 suppl. 1, S138–S143.
Lin J.-J., Chang C.-H. and Pal N. 2015 A revisit to contingency table and tests of independence: Bootstrap is preferred to Chi-square approximations as well as Fisher’s exact test. J. Biopharm. Stat. 25, 438–458.
Lyst M. J. and Bird A. 2015 Rett syndrome: a complex disorder with simple roots. Nat. Rev. Genet. 16, 261–275.
Miltenberger-Miltenyi G. and Laccone F. 2003 Mutations and polymorphisms in the human methyl CpG-binding protein MECP2. Hum. Mutat. 22, 107–115.
Monrós E., Armstrong J., Aibar E., Poo P., Canós I. and Pineda M. 2001 Rett syndrome in Spain: Mutation analysis and clinical correlations. Brain Dev. 23, S251–S253.
Mushtaq A. U., Lee Y., Hwang E., Bang J. K., Hong E., Byun Y et al. 2018 Biophysical characterization of the basic cluster in the transcription repression domain of human MeCP2 with AT-rich DNA. Biochem. Biophys. Res. Commun. 495, 145–150.
Nan X., Ng H. H., Johnson C. A., Laherty C. D., Turner B. M., Eisenman R. N. et al. 1998 Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386–389.
Neul J. L., Fang P., Barrish J., Lane J., Caeg E. B., Smith E. O. et al. 2008 Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 70, 1313–1321.
Neul J. L., Kaufmann W. E., Glaze D. G., Christodoulou J., Clarke A. J., Bahi-Buisson N. et al. 2010 Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 68, 944–950.
Nissenkorn A., Levy-Drummer R. S., Bondi O., Renieri A., Villard L., Mari F. et al. 2015 Epilepsy in Rett syndrome-Lessons from the Rett networked database. Epilepsia 56, 569–576.
Operto F. F., Mazza R., Pastorino G. M. G., Verrotti A. and Coppola G. 2019 Epilepsy and genetic in Rett syndrome: a review. Brain Behav. 9, e01250.
Pintaudi M., Calevo M., Vignoli A., Parodi E., Aiello F., Baglietto M. et al. 2010 Epilepsy in Rett syndrome: Clinical and genetic features. Epilepsy Behav. 19, 296–300.
Soffer O. D. and Sidlow R. 2016 A rare MeCP2_e1 mutation first described in a male patient with severe neonatal encephalopathy. Am. J. Med. Genet. Part A. 170, 1881–1883.
Tarquinio D. C., Hou W., Berg A., Kaufmann W. E., Lane J. B., Skinner S. A. et al. 2016 Longitudinal course of epilepsy in Rett syndrome and related disorders. Brain 140, 306–318.
Xiang F. 2000 Mutation screening in Rett syndrome patients. J. Med. Genet. 37, 250–255.
Acknowledgements
We would like to thank Dr Jeyaseelan L. (Department of Biostatistics, Christian Medical College, Vellore) for his assistance in boot strap analysis.
Author information
Authors and Affiliations
Corresponding author
Additional information
Corresponding editor: S. Ganesh
Rights and permissions
About this article
Cite this article
Kamdar, P., Thomas, M., Yoganathan, S. et al. Methyl-CpG-binding protein 2 gene mutations and its association with epilepsy: a single centre study from the Indian subcontinent. J Genet 99, 79 (2020). https://doi.org/10.1007/s12041-020-01244-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12041-020-01244-4